BNGO Stock Forecast: BioNano Genomics Inc skyrockets as Saphyr is a winner at the Cytogenics Symposium


Share:
  • NASDAQ:BNGO surges by 23.45% after regaining NASDAQ compliance.
  • BNGO’s Saphyr platform shines at the annual Next-Generation Cytogenics Symposium.
  • BNGO has the attention of noted investment firm Ark invest.

NASDAQ:BNGO continued its 2021 momentum as the red-hot genomics sector keeps hitting new highs on a daily basis. On Thursday, small-cap upstart BioNano Genomics caught the eye of value investors as the stock added 23.45% to close the trading session at $6.95, but not before hitting new 52-week highs of $7.95 during intraday hours. Shares are up over 150% already this year and as the COVID-19 pandemic continues to hit our world hard, healthcare and biogenomics are at the forefront of investor interest.

That interest was clear as BioNano Genomics presented its Saphyr platform at the Next-Generaton Cytogenics Symposium this year and impressed medical professionals with its accuracy in detecting tumors, as well as saving doctors time and money without having to run extra costly tests or scans. BNGO also announced that it would be revealing information on how Saphyr can detect genetic drivers that lead to increased susceptibility to COVID-19. The Saphyr platform is able to identify structural variants in our genes that have control over potential immune system responses. The importance of this? Determining why some people react severely to COVID-19, while some remain symptomatic. 

BNGO stock price

BioNano Genetics Inc (BNGO) stock chart

If all of that is not enough for investors, noted genomics industry investors ARK invest have also apparently been keen to know more about BNGO. ARK investor Simon Barnett was reported to be interested in speaking with BNGO’s CEO Dr. Robert Erik Holmlin late in 2020, so investors are anticipating that BNGO could be added to ARK’s genomics ETF ARK.G at some point in the near future, especially after its impressive showing at the symposium. 

Share: Feed news

Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.

If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.

FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.

The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.

Follow us on Telegram

Stay updated of all the news

Join Telegram

Recommended content


Follow us on Telegram

Stay updated of all the news

Join Telegram

Recommended content

Editors’ Picks

EUR/USD consolidates recovery above 1.0650

EUR/USD consolidates recovery above 1.0650

EUR/USD extended the recovery from intraday monthly lows to the 1.0670 zone. It is holding firm above 1.0650 after the US Dollar lost momentum during the Asian session, primarily due to a retreat in US yields.

EUR/USD News

GBP/USD trims losses and rises to 1.2300

GBP/USD trims losses and rises to 1.2300

Boosted by a weaker US Dollar, the GBP/USD rebounded from six-month lows near 1.2230 and rose to the 1.2300 area. However, the Pound remains among the worst performers following the surprise dovish stance from the Bank of England.

GBP/USD News

Gold trims weekly gains, trades around $1,920 Premium

Gold trims weekly gains, trades around $1,920

XAU/USD extended its weekly decline to $1,913.91 as the US Dollar kept marching higher following the Federal Reserve (Fed) decision to keep rates unchanged, but remark rates will remain higher for longer. Also, the Fed left the door open for one more rate hike this year. Chair Jerome Powell said the focus is on a soft landing, suggesting they are still struggling to avoid a recession.

Gold News

Tether increased its secured loans in Q2 despite commitment to reduce lending

Tether increased its secured loans in Q2 despite commitment to reduce lending

Tether Holdings has resumed the lending of its stablecoins in the form of secured loans to clients after announcing that it is set to wind down this practice less than a year ago. 

Read more

Fed Dot Plot puts more pressure on DJIA

Fed Dot Plot puts more pressure on DJIA

The Dow Jones Industrial Average (DJIA) has pulled back 0.51% so far this week, losing most of the ground after the Federal Reserve press conference on Wednesday. The US central bank once again paused interest rates but raised the specter of another hike before next year.

Read more

Forex MAJORS

Cryptocurrencies

Signatures